SCHEMBL746449

SCHEMBL746449

CC(C(=O)N1CCC2(CC1)CCN(c1ccc(OC(F)(F)F)cc1)C2)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.48
CYP3A4 P08684 12/20 0.45
USP2 O75604 10/20 0.45
CYP2C9 P11712 8/20 0.45
CYP2C19 P33261 8/20 0.45
ALDH1A1 P00352 8/20 0.45
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
MAPK1 P28482 5/20 0.45
HSD17B10 Q99714 8/20 0.45
CYP1A2 P05177 6/20 0.45
HIF1A Q16665 5/20 0.45
ALOX15 P16050 2/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
TSHR P16473 3/20 0.44
HPGD P15428 2/20 0.44
TP53 P04637 1/20 0.43
CYP2D6 P10635 1/20 0.43
CHRM4 P08173 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL747217 0.88 EPHX2 (0.54) EPHX2CYP3A4USP2CYP2C9CYP2C19
SCHEMBL3756512 0.81 LIPE (0.56)
SCHEMBL743517 0.78 MAPK1 (0.54) EPHX2CYP3A4USP2CYP2C9CYP2C19
SCHEMBL747836 0.77 EPHX2 (0.49) EPHX2CYP3A4USP2CYP2C9CYP2C19
SCHEMBL747330 0.76 EPHX2 (0.51) EPHX2CYP3A4USP2CYP2C9CYP2C19
SCHEMBL745801 0.76 EPHX2 (0.52) EPHX2
SCHEMBL748074 0.76 GRM5 (0.55) EPHX2CYP3A4USP2CYP2C9CYP2C19
SCHEMBL5301 0.76 EPHX2 (0.42) EPHX2
SCHEMBL743550 0.75 CYP3A4 (0.49) EPHX2CYP3A4USP2CYP2C9CYP2C19
SCHEMBL26552871 0.75 ALDH1A1 (0.47) EPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430023-A1 AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-03-21 EP claimed
WO-2010130665-A1 AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 WO claimed